Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1α

Early detection and improved therapies for many cancers are enhancing survival rates. Although many cytotoxic therapies are approved for aggressive or metastatic cancer; response rates are low and acquisition of de novo resistance is virtually universal. For decades; chemotherapeutic treatments for...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnason, Terra, Harkness, Troy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695877/
https://www.ncbi.nlm.nih.gov/pubmed/26501324
http://dx.doi.org/10.3390/cancers7040877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695877/
https://www.ncbi.nlm.nih.gov/pubmed/26501324
http://dx.doi.org/10.3390/cancers7040877

Ejemplares similares